Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations

BACKGROUND: There have been few studies on the efficacy of tyrosine kinase inhibitors in lung carcinomas. The purpose of this study was to evaluate the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who were positive for epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Luan, Pham, Tien, Nguyen Dinh, Hai, Nguyen Minh, Tien, Nguyen Dao, Duyen, Thi Thi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900790/
https://www.ncbi.nlm.nih.gov/pubmed/33680095
http://dx.doi.org/10.1177/1758835921992977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900790/
https://www.ncbi.nlm.nih.gov/pubmed/33680095
http://dx.doi.org/10.1177/1758835921992977

Ejemplares similares